Kura Oncology Inc. (NASDAQ:KURA) shares traded down 3.6% on Wednesday . The stock traded as low as $5.53 and last traded at $5.67, with a volume of 157,674 shares traded. The stock had previously closed at $5.88.

Several research analysts have weighed in on the company. Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $16.00 price objective on shares of Kura Oncology in a research report on Sunday, August 14th. Zacks Investment Research cut Kura Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday, August 16th.

The company’s market cap is $108.15 million. The company has a 50-day moving average price of $4.61 and a 200 day moving average price of $3.74.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, August 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.02. On average, equities analysts expect that Kura Oncology Inc. will post ($1.58) EPS for the current fiscal year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.